Patents by Inventor Robert Charles Hider
Robert Charles Hider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
3,4-DIHYDROXY-N-(1'-BENZYL-2'-HYDROXYETHYL)-2-METHYLPYRIDINE CHLORIDE, AND SYNTHESIS AND USE THEREOF
Publication number: 20220356156Abstract: The present application provides the preparation and use of a 3,4-dihydroxyl-N-(1?-benzyl-2?-hydroxyethyl)-2-methyl pyridine chloride. According to the present application, a 3,4-dihydroxyl-N-(1?-benzyl-2?-hydroxyethyl)-2-methyl pyridine chloride is directly synthesized by a one-step reaction, and the compound includes a pharmaceutically acceptable salt thereof. 3,4-dihydroxyl-N-(1?-benzyl-2?-hydroxyethyl)-2-methyl pyridine chloride has been proved to have a good antiparkinsonian activity by animal tests, and it is a class of novel antiparkinsonian drug candidates.Type: ApplicationFiled: June 26, 2022Publication date: November 10, 2022Inventors: Yongping YU, Robert Charles Hider, Xin YUAN, Feng HAN, Wenteng CHEN, Guolin ZHANG, Zudong LIU, Yu ZHANG -
Publication number: 20080200520Abstract: Iron modulator compounds of formula (I) are provided for treating amyloidoses wherein R1 is selected from H, C1-6 alkyl, C1-6 alkenyl, C1-6 hydroxyalkyl, C1-6 hydroxyalkenyl, R2 is selected from H, C1-6 alkyl, C1-6 alkenyl, C1-6 hydroxyalkyl, C1-6 hydroxyalkenyl and C6-10 aralykyl in which the aryl group of the aralkyl group is optionally substituted by hydroxy, halo or C1-4 alkyl R3 is selected from H, C1-6 alkyl, C1-6 alkenyl and C1-12 acyl; R4 is selected from H and C1-3 alkyl R5, R6 and R7 are independently selected from H, C1-6 alkyl, C3-7 aryl, and C1-10 aralkyl; the alkyl, aryl and aralkyl groups being optionally substituted by one or more halo, hydroxy and nitro groups or R5 and R7 together with the nitrogen atom to which they are bonded form a heterocyclic ring optionally substituted by one or more hydroxyl groups or a pharmaceutically acceptable tautomer, ester or addition salt thereof.Type: ApplicationFiled: March 31, 2006Publication date: August 21, 2008Inventors: Robert Charles Hider, Alessandra Gaeta, Zu Dong Liu
-
Patent number: 7361685Abstract: The present invention provides compounds of formula (I) and analogues or derivatives thereof for the treatment of skin conditions, such as Vitiligo, which are treatable by the stimulation of melanocyte proliferation and also for treating skin cancer.Type: GrantFiled: January 15, 2002Date of Patent: April 22, 2008Assignee: Oregon Health & Science UniversityInventors: Amala Soumyanath Raman, Robert Charles Hider, Radhakrishnan Venkatasamy
-
Publication number: 20040254165Abstract: The present invention provides compounds of formula (I) and analogues or derivatives thereof for the treatment of skin conditions, such as Vitiligo, which are treatable by the stimulation of melanocyte proliferation and also for treating skin cancer. The compounds may also be used to cosmetically enhance the natural coloration of the skin.Type: ApplicationFiled: January 30, 2004Publication date: December 16, 2004Inventors: Amala Soumyanath, Robert Charles Hider, Radhakrishnan Venkatasamy
-
Patent number: 6635631Abstract: The present invention is directed to complexes comprising iron in the ferric state and a hydroxypyrone. The present invention is also directed to methods of making such complexes and to the use of such complexes in the treatment and prevention of iron deficiency disorders including iron deficiency anaemia.Type: GrantFiled: October 25, 2001Date of Patent: October 21, 2003Assignee: Vitra Pharmaceuticals, Ltd.Inventors: Michael Arthur Stockham, Robert Charles Hider
-
Publication number: 20030069218Abstract: The present invention is directed to complexes comprising iron in the ferric state and a hydroxypyrone. The present invention is also directed to methods of making such complexes and to the use of such complexes in the treatment and prevention of iron deficiency disorders including iron deficiency anaemia.Type: ApplicationFiled: October 25, 2001Publication date: April 10, 2003Inventors: Michael Arthur Stockham, Robert Charles Hider
-
Patent number: 6506911Abstract: A novel 3-hydroxypyridin-4-one compound of formula I is provided wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, R3 is selected from hydrogen and C1-6 alkyl; and R4 is selected from hydrogen, C1-6 alkyl and a group as described for R2; characterised in that R2 is selected from groups (i) —CONH—R5 (ii) —CH2NHCO—R5 (iii) —SO2NH—R5 (iv) —CH2NHSO2—R5 (v) —CR6R6OR7 (viii) —CONHCOR5 wherein R5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C1-3 alkyl, aryl and C7-13 aralkyl, R6 is independently selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl, and R7 is selected from hydrogen, C1-13 alkyl, aryl and C7Type: GrantFiled: September 4, 2001Date of Patent: January 14, 2003Assignee: BTG International LimitedInventors: Robert Charles Hider, Gary Stuart Tilbrook, Zudong Liu
-
Patent number: 6448273Abstract: A compound of formula I wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, and R3 is selected from hydrogen and C1-6 alkyl; characterized in that R2 is selected from groups (i) —CONH—R5 (ii)—CR6R6OR7 (iii) —CONHCOR5 and (iv) —CON(CnH2n+1)2 R4 is selected from hydrogen, C1-6 alkyl and a group as described for R2; R5 is selected from hydrogen and optionally hydroxy, alkoxy, aryloxy or aralkoxy substituted C1-13 alkyl, aryl and C7-13 alkyl R6 is independently selected from hydrogen and C1-13 alkyl, R7 is selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl or a pharmaceutically acceptable salt of any such compound and CnH2n+1 is C1-6alkyl with the proviso that the compoundType: GrantFiled: November 30, 1999Date of Patent: September 10, 2002Assignee: BTG International LimitedInventors: Robert Charles Hider, Gary Stuart Tilbrook, Zudong Liu
-
Publication number: 20020068758Abstract: A novel 3-hydroxypyridinone compound of formula I is provided 1Type: ApplicationFiled: September 4, 2001Publication date: June 6, 2002Applicant: BTG International Limited.Inventors: Robert Charles Hider, Gary Stuart Tilbrook, Zudong Liu
-
Patent number: 6339080Abstract: The present invention is directed to complexes comprising iron in the ferric state and a hydroxypyrone. The present invention is also directed to methods of making such complexes and to the use of the complexes in the treatment and prevention of iron deficiency disorders including iron deficiency anaemia.Type: GrantFiled: December 9, 1997Date of Patent: January 15, 2002Assignee: Vitra Pharmaceuticals Ltd.Inventors: Michael Arthur Stockham, Robert Charles Hider
-
Patent number: 6335353Abstract: A novel 3-hydroxypyridin-4-one compound of formula I is provided wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, R3 is selected from hydrogen and C1-6alkyl; and R4 is selected from hydrogen, C1-6alkyl and a group as described for R2; characterised in that R2 is selected from groups —CONH—R5 (i) —CH2NHCO—R5 (ii) —SO2NH—R5 (iii) —CH2NHSO2—R5 (iv) —CR6R6OR7 (v) —CONHCOR5 (viii) wherein R5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C1-13 alkyl, aryl and C71-13 aralkyl, R6 is independently selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl,Type: GrantFiled: November 10, 1999Date of Patent: January 1, 2002Assignee: BTG International LimitedInventors: Robert Charles Hider, Gary Stuart Tilbrook, Zudong Liu
-
Patent number: 6132706Abstract: The invention provides a physiologically acceptable polymer comprising a backbone to which are attached guanidino groups, the polymer having a minimum molecular weight of 10,000. The invention also extends to foodstuffs and pharmaceutical compositions comprising the physiologically acceptable polymer. Such foodstuffs and compositions are of value in controlling phosphate levels in the body.Type: GrantFiled: November 28, 1997Date of Patent: October 17, 2000Assignee: BTG International LimitedInventors: Robert Charles Hider, Anthony Canas-Rodriguez
-
Patent number: 5968499Abstract: A polystyrene polymer crosslinked by 1.5% to 8% with divinylbenzene based on the total weight of the polymer and having a minimum weight average molecular weight of 10000 wherein 50 to 100% of the aromatic groups of the polystyrene are substituted by at least one --(R.sup.1).sub.n --NHR.sup.2 group wherein R.sup.1 represents a straight or branched chain alkylene or cycloalkylene group of 1 to 6 carbon atoms and n is 0 or 1 and NHR.sup.2 represents a guanidino group of formula --NH--C(.dbd.NH)NH.sub.2 or a biguanidino group of formula --NH--C(.dbd.NH)--NH--C(.dbd.NH)--NH.sub.2 for use in therapy.Type: GrantFiled: July 15, 1997Date of Patent: October 19, 1999Assignee: BTG International LimitedInventors: Robert Charles Hider, Brian Leonard Goodwin
-
Patent number: 5880208Abstract: The invention provides a physiologically acceptable polymer comprising a backbone to which are attached guanidino groups, the polymer having a minimum molecular weight of 10,000. The invention also extends to foodstuffs and pharmaceutical compositions comprising the physiologically acceptable polymer. Such foodstuffs and compositions are of value in controlling phosphate levels in the body.Type: GrantFiled: August 28, 1997Date of Patent: March 9, 1999Assignee: BTG International LimitedInventors: Robert Charles Hider, Anthony Canas-Rodriguez
-
Patent number: 5851518Abstract: The invention provides a physiologically acceptable polymer comprising a backbone to which are attached guanidino groups, the polymer having a minimum molecular weight of 10,000. The invention also extends to foodstuffs and pharmaceutical compositions comprising the physiologically acceptable polymer. Such foodstuffs and compositions are of value in controlling phosphate levels in the body.Type: GrantFiled: August 28, 1997Date of Patent: December 22, 1998Assignee: British Technology Group LimitedInventors: Robert Charles Hider, Anthony Canas-Rodriguez
-
Patent number: 5698190Abstract: The invention provides a physiologically acceptable polymer comprising a backbone to which are attached guanidino groups, the polymer having a minimum molecular weight of 10,000. The invention also extends to foodstuffs and pharmaceutical compositions comprising the physiologically acceptable polymer. Such foodstuffs and compositions are of value in controlling phosphate levels in the body.Type: GrantFiled: July 13, 1995Date of Patent: December 16, 1997Assignee: British Technology Group Ltd.Inventors: Robert Charles Hider, Anthony Canas-Rodriguez